TY - JOUR
T1 - Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
AU - Jain, Preetesh
AU - Keating, Michael
AU - Wierda, William
AU - Estrov, Zeev
AU - Ferrajoli, Alessandra
AU - Jain, Nitin
AU - George, Binsah
AU - James, Danelle
AU - Kantarjian, Hagop
AU - Burger, Jan
AU - O'Brien, Susan
N1 - Publisher Copyright:
© 2015 by The American Society of Hematology.
PY - 2015/3/26
Y1 - 2015/3/26
N2 - Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at our center. Thirty-three (26%) patients have discontinued ibrutinib to date. Themajority of those patients had high-risk features: 94% with unmutated immunoglobulin heavy chain variable gene rearrangement, 58% with del(17p) by fluorescence in situ hybridization, and 54% with a complex karyotype. Causes of discontinuation were disease transformation (7), progressive CLL (7), stem cell transplantation (3), adverse events (11), serious adverse events/deaths (3), and miscellaneous reasons (2). Twenty five patients (76%) died after discontinuing ibrutinib; the median overall survival was 3.1 months after discontinuation. Most patients with RR-CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes.
AB - Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at our center. Thirty-three (26%) patients have discontinued ibrutinib to date. Themajority of those patients had high-risk features: 94% with unmutated immunoglobulin heavy chain variable gene rearrangement, 58% with del(17p) by fluorescence in situ hybridization, and 54% with a complex karyotype. Causes of discontinuation were disease transformation (7), progressive CLL (7), stem cell transplantation (3), adverse events (11), serious adverse events/deaths (3), and miscellaneous reasons (2). Twenty five patients (76%) died after discontinuing ibrutinib; the median overall survival was 3.1 months after discontinuation. Most patients with RR-CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84926178507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926178507&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-09-603670
DO - 10.1182/blood-2014-09-603670
M3 - Article
C2 - 25573991
AN - SCOPUS:84926178507
SN - 0006-4971
VL - 125
SP - 2062
EP - 2067
JO - Blood
JF - Blood
IS - 13
ER -